Orphazyme A/S announced that the company's Board of Directors has appointed Kim Stratton as the new Chief Executive Officer of Orphazyme, succeeding Anders Hinsby. Kim Stratton will take up her new position on October 1, 2019. As Orphazyme enters a new chapter in its development, from being an entrepreneurial R&D company to a company with significant growth aspirations, an emerging late-stage pipeline and moving into the pre-commercial phase, Anders Hinsby initiated discussions with the Board of Directors to resign from his position as Chief Executive Officer. Anders co-founded Orphazyme ten years ago and has led its successful evolution. Anders Hinsby will remain with the company through the transition period. Kim is a senior and driven executive with more than 25 years' global commercial experience from biopharmaceuticals. She brings significant general management experience across multiple geographies, including UK, US, Europe, and emerging markets. Kim joins from Shire Pharmaceuticals, where she served as Head International Commercial for Shire's Specialty and Rare Diseases portfolio. Kim Stratton will take up her position as Chief Executive Officer on October 1, 2019.